# What an older sarcopenia trial measured with a body scan

- Article ID: research-399
- Product: Trevogrumab (trevogrumab-1mg-3ml)
- Canonical page: https://heritagebiolabs.com/research-library/articles/399-what-an-older-sarcopenia-trial-measured-with-a-body-scan
- Product collection: https://heritagebiolabs.com/research-library/products/trevogrumab
- Product page: https://heritagebiolabs.com/product/trevogrumab-1mg-3ml
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2013, 2016, 2018, 2024, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids connected by peptide bonds. They can act as signals or bind other molecules. Trevogrumab, also called REGN1033 in earlier studies, is a larger investigational antibody that blocks myostatin. An older randomized study in people with sarcopenia tested whether the antibody changed lean body mass over 12 weeks. [1, 2, 3]

The study compared three groups receiving the investigational antibody with a placebo group. The primary outcome in the European trial results was percentage change in total lean body mass measured by dual-energy X-ray absorptiometry, or DXA. The estimated group averages increased by about 1.2% to 1.8% with the antibody and declined by about 0.5% with placebo. These values describe the trial’s primary scan measurement. The registry also gives the number of participants in each group who had the measurements needed for this analysis. [1]

The registry also lists secondary physical performance measures. For example, investigators assessed aspects of gait in a timed walking test. These measures address a different outcome from how much fat-free tissue a scan estimates. A scan can detect a difference in tissue composition while a walking test depends on multiple systems, including strength, balance and coordination. Reporting one result cannot substitute for examining the other. [1]

This study examined people with sarcopenia and tested the antibody against placebo over a short period. It did not study the antibody during semaglutide-associated weight change. Its older European results record is direct human evidence for the scan question in its study population. Comparisons in other settings, including adding trevogrumab to a weight-management medication, need their own trial designs and outcomes. [1, 2, 3]

## Sources

1. Regeneron Pharmaceuticals, Inc. EudraCT Number 2013-003134-33 - Clinical trial results. EU Clinical Trials Register (publication 2018-05-01). <https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003134-33/results>
2. Regeneron Pharmaceuticals, Inc. A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Safety and Efficacy of 3-month Subcutaneous REGN1033 Treatment in Patients With Sarcopenia. ClinicalTrials.gov (publication 2013-10-16, record updated 2016-03-28). <https://clinicaltrials.gov/study/NCT01963598>
3. Regeneron Pharmaceuticals, Inc. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity. ClinicalTrials.gov (publication 2024-03-07, record updated 2026-09-01). <https://clinicaltrials.gov/study/NCT06299098>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 080 - Trevogrumab and Triptorelin GnRH.docx; article 399; content SHA-256 638d4be46cce830fc939a5edbed3d2622a5f357997f34876c4dc226909295091.
